Physician profile
Santiago Munoz
NPI 1578531190
$877,104.67
in general payments reported to CMS, 2019-2025
16 companies · $385K in 2025
The $385K reported for 2025 was more than what 99% of Transplant Hepatology providers received nationally (typical 2025 total: $508).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66K · 2020: $23K · 2021: $35K · 2022: $19K · 2023: $129K · 2024: $220K · 2025: $385K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $631K · Travel and Lodging: $72K · Consulting Fee: $18K · Food and Beverage: $13K · Education: $74.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $630,500.50 |
| Travel and Lodging | $72,367.84 |
| Consulting Fee | $18,115.50 |
| Food and Beverage | $12,738.71 |
| Education | $74.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $357,858.69 | 2024-2025 | Rezdiffra, Resmetirom |
| Mallinckrodt Hospital Products INC. | $332,224.46 | 2021-2025 | Terlivaz |
| Gilead Sciences, INC. | $82,845.17 | 2019-2023 | Epclusa |
| Abbvie INC. | $49,147.86 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $24,277.05 | 2024-2025 | Bylvay, Iqirvo |
| Mirum Pharmaceuticals, INC. | $11,156.65 | 2024-2025 | Livmarli |
| Shionogi INC | $7,806.30 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $7,244.17 | 2019-2021 | |
| Dova Pharmaceuticals | $3,874.53 | 2019 | |
| Alexion Pharmaceuticals, INC. | $229.34 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $190.21 | 2019-2024 | Xifaxan |
| Haemonetics Corporation | $100.19 | 2022-2023 | Teg6s Hemostasis System |
| Novo Nordisk INC | $64.54 | 2025 | Wegovy |
| Albireo Pharma, INC. | $36.53 | 2024 | Bylvay |
| Si-Bone, INC. | $34.93 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertos Medical, INC. | $14.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Santiago Munoz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.